On March 1, 2007, Samaritan signed an exclusive licensing agreement with Shire Human Genetic Therapies to market and sell Elaprase in Greece and Cyprus. Since the launch of Elaprase, Samaritan has been marketing Elaprase on a named patient basis where doctors have to specify the patients need for the drug.
Elaprase is an enzyme replacement therapy designed to replace enzymes that are deficient or absent in people with Hunter syndrome.